544   Supplementary material:
545
546

547
548
549
550   **Supplementary Figure 1:** Location of the tumor in relation to the lateral ventricles (LV). **A & B,**
551   T1-weighted post-contrast MR images, axial and coronal view respectively, showing CE tumor
552   bordering the LV. **C & D,** T1-weighted post-contrast MR images, axial and coronal view
553   respectively.
554
555
556
557
558
559

560
561

562
563
564 **Supplementary Figure 2:** Illustration of the Region of interest (ROI) for each volumetric
565 measurement. **(A)** Contrast-enhancing ROI (blue) on pre-operative MRI axial T1 post-contrast
566 sequence. **(B)** Cystic/Necrosis ROI (yellow) on pre-operative MRI axial T1 post-contrast
567 sequence. **(C)** FLAIR ROI (orange) on pre-operative MRI axial FLAIR sequence. **(D)** FLAIR ROI
568 (green) on post-operative MRI axial FLAIR sequence.
569
570
571
572
573

Distribution of SMR Percentages

574
575   **Supplementary Figure 3:** Histogram showing distribution of SMR percentages in our cohort.
576
577
578

PFS of Patients at SMR Threshold of 20%

579
580   **Supplementary Figure 4:** PFS by SMR threshold of 20% among patients with GBM with GTR
581   of the CE. The mean PFS for patients receiving <20% SMR was 8.7 months compared to 9.6
582   months for >20% SMR patients **(P = 0.046)**.

583

PFS of Patients at SMR Threshold of 40%

584
585   **Supplementary Figure 5:** PFS by SMR threshold of 40% among patients with GBM with GTR
586   of the CE. The mean PFS for patients receiving <40% SMR was 8.9 months compared to 10.6
587   months for >40% SMR patients **(P < 0.001)**.
588

Supplementary table 1: Univariate Analysis of SMR (%) by Location			
Variable	**Yes**	**No**	**p Value**
Deep-seated	24.8%	31.9%	0.50
Non-Eloquent	30.0%	26.4%	0.73

589

Supplementary Table 2: Univariate Analysis of SMR and PFS		
Variable	HR (95% CI)	p Value
% SMR on T2-weighted FLAIR		
1% Increments	1.00 (0.99 – 1.01)	0.38
10% Increments	0.92 (0.85 – 0.99)	**0.04**
> 20%	0.58 (0.34 – 0.99)	**0.05**
> 30%	0.50 (0.30 – 0.85)	**0.01**
> 40%	0.52 (0.31 – 0.86)	**0.01**
> 50%	0.64 (0.38 – 1.06)	0.08
Age		
≥ 65 yrs	2.34 (1.31 – 4.19)	**<0.01**
Gender		
Male sex	0.87 (0.52 – 1.45)	0.59
MGMT		
Promoter metylation	0.61 (0.48 - 0.94)	**0.04**
KPS		
>70	0.48 (0.24 – 0.86)	**0.03**
Charlson Comorbidity Index	1.20 (1.01 – 1.43)	**0.03**

590   Boldface type indicates statistical significance ($p < 0.05$).